• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
IMU
Click for more information
0.00% 3.8¢

IMUGENE LIMITED - Announcements

Market Cap $386.7M  ! watchlist Created with Sketch. Add to my watchlist

Imugene Limited is a clinical-stage immune-oncology company. It is engaged in developing... Imugene Limited is a clinical-stage immune-oncology company. It is engaged in developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Its platform technology seeks to harness and promote the body’s immune system against cancerous tumors. Its product pipeline includes an off-the-shelf (allogeneic) cell therapy CAR T drug Azer-Cel (azercabtagene zapreleucel) which targets CD19 to attack blood cancer. Its pipeline includes an Oncolytic Virus and B-Cell Immunotherapies aimed at treating a variety of cancers in combination with standard of care drugs and immunotherapies. Its lead candidate is a chimeric vaccinia (pox) virus known as CF33, which is a combination of genomic sequences from multiple vaccinia virus strains to generate a new, safer and more potent virus. Its Chimeric antigen receptor (CAR)-engineered T cells (CAR T) are T cells redirected against tumors through engineered expression of CARs. More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
IMU AusBioInvest Investor Presentation24/10/17
IMU Response to ASX Price QueryPRICE SENSITIVE17/10/17
IMU Expert Briefing - Latest Clinical and Commercial Advances16/10/17
IMU Notice of Annual General Meeting & Proxy Form13/10/17
IMU Notice of Annual General Meeting/Proxy Form12/10/17
IMU IMU Receives $1.1m R&D Tax RefundPRICE SENSITIVE11/10/17
IMU Investor Presentation06/10/17
IMU Appendix 3B - ESOP21/09/17
IMU First Patient Dosing Commences of HER-VaxxPRICE SENSITIVE31/08/17
IMU Appendix 4G31/08/17
IMU Appendix 4E and Annual ReportPRICE SENSITIVE31/08/17
IMU Appendix 3B (Exercise of Options) and 708A Notice25/08/17
IMU Appendix 4C - quarterlyPRICE SENSITIVE31/07/17
IMU Imugene granted Canadian patent for Her-Vaxx cancer vaccinePRICE SENSITIVE21/07/17
IMU Investor Presentation17/07/17
IMU Change of address26/06/17
IMU Appendix 4C - quarterly and Commentry Q3PRICE SENSITIVE28/04/17
IMU Section 708A Notice19/04/17
IMU IMU Raises $3.0m from Options PlanPRICE SENSITIVE06/04/17
IMU Appendix 3B (Exercise of Options)06/04/17
IMU $1.35 million Options UnderwrittenPRICE SENSITIVE30/03/17
IMU Appendix 3B (Exercise of Options)27/03/17
IMU Imugene March Newsletter14/03/17
IMU Appendix 3B - Exercise of Options10/03/17
IMU Update on Imugene Option08/03/17
IMU Letter to Option Holders IMUO08/03/17
IMU Half Year Results Summary28/02/17
IMU Half Year Report and AccountsPRICE SENSITIVE28/02/17
IMU Intellectual Property Strengthened Around Lead Clinical DrugPRICE SENSITIVE27/02/17
IMU Appendix 3B - Exercise of Options24/02/17
IMU BMC Cancer journal publishes encouraging HER-Vaxx researchPRICE SENSITIVE13/02/17
IMU Letter to Option Holders - IMUO08/02/17
IMU Appendix 3B - Exercise of Options31/01/17
IMU Appendix 4C - quarterlyPRICE SENSITIVE27/01/17
IMU Investor Presentation09/01/17
IMU Investor Newsletter20/12/16
IMU Imugene progresses mimotope platformPRICE SENSITIVE19/12/16
IMU Response to ASX Aware QueryPRICE SENSITIVE16/12/16
IMU Response to ASX Price QueryPRICE SENSITIVE13/12/16
IMU Acquisition of immuno-oncology technologyPRICE SENSITIVE13/12/16
IMU Imugene Corporate Presentation02/12/16
IMU Response to ASX Price QueryPRICE SENSITIVE25/11/16
IMU Leslie Chong Appointed Chief Executive OfficerPRICE SENSITIVE21/11/16
IMU Change of Director's Interest Notice09/11/16
IMU Change in substantial holding07/11/16
IMU Imugene Commences HER-Vaxx Phase 1b/2 Gastric Cancer StudyPRICE SENSITIVE07/11/16
IMU Ceasing to be a substantial holder04/11/16
IMU Appendix 3B, 708A Notice & Listing Rule 3.10.5A information-IMU.AX 03/11/16
IMU Appendix 3B, 708A Notice & Listing Rule 3.10.5A information03/11/16
IMU Results of Meeting-IMU.AX 02/11/16
IMU AGM Presentation-IMU.AX 02/11/16
IMU Director Resignation - Final Director Interest Notice-IMU.AX 31/10/16
IMU Becoming a substantial holder-IMU.AX 31/10/16
IMU Appendix 4C - quarterly-IMU.AX PRICE SENSITIVE27/10/16
IMU Appendix 3B-IMU.AX 27/10/16
IMU Imugene Share Placement raises $3.2 million-IMU.AX PRICE SENSITIVE21/10/16
IMU Trading Halt-IMU.AX PRICE SENSITIVE19/10/16
IMU Notice of Annual General Meeting/Proxy Form-IMU.AX 30/09/16
IMU Appendix 4G-IMU.AX 28/09/16
IMU Annual Report to shareholders-IMU.AX 28/09/16
IMU Imugene receives $1.3m R&D Tax Refund-IMU.AX PRICE SENSITIVE22/09/16
IMU Imugene successfully completes preclinical animal studies-IMU.AX PRICE SENSITIVE20/09/16
IMU Preliminary Final Report-IMU.AX PRICE SENSITIVE30/08/16
IMU Imugene Final Cancer Vaccine Doses Delivered to GMP Depot-IMU.AX PRICE SENSITIVE30/08/16
IMU Imugene Receives Approval to Start Gastric Cancer Study-IMU.AX PRICE SENSITIVE22/08/16
IMU Imugene Receives Institutional Review Board approval-IMU.AX PRICE SENSITIVE11/08/16
IMU Appendix 4C - quarterly-IMU.AX PRICE SENSITIVE29/07/16
IMU Imugene Receives Institutional Review Board Approval-IMU.AX PRICE SENSITIVE11/07/16
IMU Becoming a substantial holder-IMU.AX 06/07/16
IMU Ceasing to be a substantial holder-IMU.AX 15/06/16
IMU Corporate Development Update-IMU.AX 27/05/16
IMU Appendix 4C - quarterly-IMU.AX PRICE SENSITIVE29/04/16
IMU Regulatory package submission for Her-Vaxx in Hong Kong-IMU.AX PRICE SENSITIVE21/04/16
IMU Shareholder Newsletter-IMU.AX 13/04/16
IMU Dr Yelena Janjigian appointed as SAB member-IMU.AX 12/04/16
IMU Manufacturing UpdatePRICE SENSITIVE07/03/16
IMU Imugene Results for December Half Year29/02/16
IMU Half Yearly Report and AccountsPRICE SENSITIVE29/02/16
IMU Imugene to present at the RedChip Global Online Conference10/02/16
IMU Appendix 4C - quarterlyPRICE SENSITIVE27/01/16
IMU Partnership to Develop Mimotope Immuno-Oncology PlatformPRICE SENSITIVE20/01/16
IMU Final Director's Interest Notice (OB)18/01/16
IMU Noble Financial Capital Markets Investor Presentation15/01/16
IMU Biotech Showcase Presentation11/01/16
IMU Initial Director's Interest Notice AU07/01/16
IMU Dr. Anton Uvarov appointed Non-Executive Director05/01/16
IMU Stuart Roberts named as Head of Corporate Development04/01/16
IMU Imugene to present at the 2016 Biotech Showcase22/12/15
IMU Imugene key HER-Vaxx patent granted in EuropePRICE SENSITIVE18/12/15
IMU Director Resignation - Mr. Otto Buttula17/12/15
IMU Change of Director's Interest Notice (PH)14/12/15
IMU Novotech appointed Contract Research OrganisationPRICE SENSITIVE14/12/15
IMU Change of Director's Interest Notice (OB)11/12/15
IMU Change of Director's Interest Notice (PH)08/12/15
IMU Change of Director's Interest Notice (OB)30/11/15
IMU Change of Director's Interest Notice (OB)23/11/15
IMU Change of Director's Interest Notice (PH)13/11/15
IMU Change of Director's Interest Notice (OB)13/11/15
IMU Change of Director's Interest Notice (CW)13/11/15
IMU Appendix 3B09/11/15
IMU AusBioInvest Investor Presentation
24/10/17
IMU Response to ASX Price Query
17/10/17PRICE SENSITIVE
IMU Expert Briefing - Latest Clinical and Commercial Advances
16/10/17
IMU Notice of Annual General Meeting & Proxy Form
13/10/17
IMU Notice of Annual General Meeting/Proxy Form
12/10/17
IMU IMU Receives $1.1m R&D Tax Refund
11/10/17PRICE SENSITIVE
IMU Investor Presentation
06/10/17
IMU Appendix 3B - ESOP
21/09/17
IMU First Patient Dosing Commences of HER-Vaxx
31/08/17PRICE SENSITIVE
IMU Appendix 4G
31/08/17
IMU Appendix 4E and Annual Report
31/08/17PRICE SENSITIVE
IMU Appendix 3B (Exercise of Options) and 708A Notice
25/08/17
IMU Appendix 4C - quarterly
31/07/17PRICE SENSITIVE
IMU Imugene granted Canadian patent for Her-Vaxx cancer vaccine
21/07/17PRICE SENSITIVE
IMU Investor Presentation
17/07/17
IMU Change of address
26/06/17
IMU Appendix 4C - quarterly and Commentry Q3
28/04/17PRICE SENSITIVE
IMU Section 708A Notice
19/04/17
IMU IMU Raises $3.0m from Options Plan
06/04/17PRICE SENSITIVE
IMU Appendix 3B (Exercise of Options)
06/04/17
IMU $1.35 million Options Underwritten
30/03/17PRICE SENSITIVE
IMU Appendix 3B (Exercise of Options)
27/03/17
IMU Imugene March Newsletter
14/03/17
IMU Appendix 3B - Exercise of Options
10/03/17
IMU Update on Imugene Option
08/03/17
IMU Letter to Option Holders IMUO
08/03/17
IMU Half Year Results Summary
28/02/17
IMU Half Year Report and Accounts
28/02/17PRICE SENSITIVE
IMU Intellectual Property Strengthened Around Lead Clinical Drug
27/02/17PRICE SENSITIVE
IMU Appendix 3B - Exercise of Options
24/02/17
IMU BMC Cancer journal publishes encouraging HER-Vaxx research
13/02/17PRICE SENSITIVE
IMU Letter to Option Holders - IMUO
08/02/17
IMU Appendix 3B - Exercise of Options
31/01/17
IMU Appendix 4C - quarterly
27/01/17PRICE SENSITIVE
IMU Investor Presentation
09/01/17
IMU Investor Newsletter
20/12/16
IMU Imugene progresses mimotope platform
19/12/16PRICE SENSITIVE
IMU Response to ASX Aware Query
16/12/16PRICE SENSITIVE
IMU Response to ASX Price Query
13/12/16PRICE SENSITIVE
IMU Acquisition of immuno-oncology technology
13/12/16PRICE SENSITIVE
IMU Imugene Corporate Presentation
02/12/16
IMU Response to ASX Price Query
25/11/16PRICE SENSITIVE
IMU Leslie Chong Appointed Chief Executive Officer
21/11/16PRICE SENSITIVE
IMU Change of Director's Interest Notice
09/11/16
IMU Change in substantial holding
07/11/16
IMU Imugene Commences HER-Vaxx Phase 1b/2 Gastric Cancer Study
07/11/16PRICE SENSITIVE
IMU Ceasing to be a substantial holder
04/11/16
IMU Appendix 3B, 708A Notice & Listing Rule 3.10.5A information-IMU.AX
03/11/16
IMU Appendix 3B, 708A Notice & Listing Rule 3.10.5A information
03/11/16
IMU Results of Meeting-IMU.AX
02/11/16
IMU AGM Presentation-IMU.AX
02/11/16
IMU Director Resignation - Final Director Interest Notice-IMU.AX
31/10/16
IMU Becoming a substantial holder-IMU.AX
31/10/16
IMU Appendix 4C - quarterly-IMU.AX
27/10/16PRICE SENSITIVE
IMU Appendix 3B-IMU.AX
27/10/16
IMU Imugene Share Placement raises $3.2 million-IMU.AX
21/10/16PRICE SENSITIVE
IMU Trading Halt-IMU.AX
19/10/16PRICE SENSITIVE
IMU Notice of Annual General Meeting/Proxy Form-IMU.AX
30/09/16
IMU Appendix 4G-IMU.AX
28/09/16
IMU Annual Report to shareholders-IMU.AX
28/09/16
IMU Imugene receives $1.3m R&D Tax Refund-IMU.AX
22/09/16PRICE SENSITIVE
IMU Imugene successfully completes preclinical animal studies-IMU.AX
20/09/16PRICE SENSITIVE
IMU Preliminary Final Report-IMU.AX
30/08/16PRICE SENSITIVE
IMU Imugene Final Cancer Vaccine Doses Delivered to GMP Depot-IMU.AX
30/08/16PRICE SENSITIVE
IMU Imugene Receives Approval to Start Gastric Cancer Study-IMU.AX
22/08/16PRICE SENSITIVE
IMU Imugene Receives Institutional Review Board approval-IMU.AX
11/08/16PRICE SENSITIVE
IMU Appendix 4C - quarterly-IMU.AX
29/07/16PRICE SENSITIVE
IMU Imugene Receives Institutional Review Board Approval-IMU.AX
11/07/16PRICE SENSITIVE
IMU Becoming a substantial holder-IMU.AX
06/07/16
IMU Ceasing to be a substantial holder-IMU.AX
15/06/16
IMU Corporate Development Update-IMU.AX
27/05/16
IMU Appendix 4C - quarterly-IMU.AX
29/04/16PRICE SENSITIVE
IMU Regulatory package submission for Her-Vaxx in Hong Kong-IMU.AX
21/04/16PRICE SENSITIVE
IMU Shareholder Newsletter-IMU.AX
13/04/16
IMU Dr Yelena Janjigian appointed as SAB member-IMU.AX
12/04/16
IMU Manufacturing Update
07/03/16PRICE SENSITIVE
IMU Imugene Results for December Half Year
29/02/16
IMU Half Yearly Report and Accounts
29/02/16PRICE SENSITIVE
IMU Imugene to present at the RedChip Global Online Conference
10/02/16
IMU Appendix 4C - quarterly
27/01/16PRICE SENSITIVE
IMU Partnership to Develop Mimotope Immuno-Oncology Platform
20/01/16PRICE SENSITIVE
IMU Final Director's Interest Notice (OB)
18/01/16
IMU Noble Financial Capital Markets Investor Presentation
15/01/16
IMU Biotech Showcase Presentation
11/01/16
IMU Initial Director's Interest Notice AU
07/01/16
IMU Dr. Anton Uvarov appointed Non-Executive Director
05/01/16
IMU Stuart Roberts named as Head of Corporate Development
04/01/16
IMU Imugene to present at the 2016 Biotech Showcase
22/12/15
IMU Imugene key HER-Vaxx patent granted in Europe
18/12/15PRICE SENSITIVE
IMU Director Resignation - Mr. Otto Buttula
17/12/15
IMU Change of Director's Interest Notice (PH)
14/12/15
IMU Novotech appointed Contract Research Organisation
14/12/15PRICE SENSITIVE
IMU Change of Director's Interest Notice (OB)
11/12/15
IMU Change of Director's Interest Notice (PH)
08/12/15
IMU Change of Director's Interest Notice (OB)
30/11/15
IMU Change of Director's Interest Notice (OB)
23/11/15
IMU Change of Director's Interest Notice (PH)
13/11/15
IMU Change of Director's Interest Notice (OB)
13/11/15
IMU Change of Director's Interest Notice (CW)
13/11/15
IMU Appendix 3B
09/11/15
refresh Created with Sketch. REFRESH
 
(20min delay)
Last
3.8¢ 		Change
0.000(0.00%) 		Mkt cap ! $386.7M
Open High Low Value Volume
0.0¢ 0.0¢ 0.0¢ $0 0

Buyers (Bids)

No. Vol. Price($)
2 1050000 3.9¢
 

Sellers (Offers)

Price($) Vol. No.
3.7¢ 134148 3
View Market Depth
Last trade - 09.13am 26/11/2024 (20 minute delay) ?
IMU (ASX) Chart

Top Stories

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

Who the MinRes Board has decided to move on faster may or may not be amusing, depending on how much you've lost.
Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects Pan Asia Metals has scored $35 million from a New York private equity firm at the same time as the company's big rebrand push begins.
This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game Today, one small pill holds the potential to transform cognitive medicine by addressing conditions like depression and Alzheimer’s. 
ASX's new CHESS replacement set for 2026. Just ignore ASIC's lawsuit ASX Ltd (ASX:ASX) – the operator of the Australian bourse – has released a fresh update on its controversial CHESS system replacement.
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025 Samples among the highest-ever-graded uranium soil samples recorded in mineral exploration history, and an imminent drill run.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.